Dynavax Appoints Daniel Kisner, M.D. to Board of Directors
July 22, 2010 16:30 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - July 22, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Daniel Kisner, M.D. to its Board of Directors. The addition of Dr....
Dynavax Initiates First Human Trial in Universal Flu Vaccine Program
July 07, 2010 09:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - July 7, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the first human clinical trial in its Universal Flu vaccine program. The Phase 1...
Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine
July 06, 2010 16:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - July 6, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the award of a $600,000 grant from the National Institutes of Health (NIH) to explore...
NATURE Publishes New Dynavax Findings on Novel Role of TLRs in Lupus
June 16, 2010 13:18 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - June 16, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in NATURE new data that may explain the resistance of lupus patients to glucocorticoid...
Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue Immunizations
May 27, 2010 09:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - May 27, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3...
Dynavax Completes Over 2000 First Immunizations in Phase 3 Study
May 06, 2010 16:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - May 6, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported completing the first immunizations of over 2,000 subjects enrolled in its large-scale...
Dynavax Reports 2010 First Quarter Financial Results
May 06, 2010 09:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - May 6, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March
31, 2010, including $30.1 million in cash...
Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue Immunizations
April 27, 2010 16:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - April 27, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing...
Dynavax Reports Positive Data on Universal Flu Vaccine Candidate
April 26, 2010 16:50 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - April 26, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today presented preclinical data that confirms the expected immunogenicity and mechanistic effects...
Dynavax's Chronic Kidney Disease Study Confirms HEPLISAV's Enhanced Seroprotection Against HBV Infection
April 14, 2010 16:36 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - April 14, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today presented Phase 2 clinical data that demonstrate HEPLISAV™'s immunogenicity and rapid...